Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17079524 | 1.00 | TSHR (0.46) | TSHRLPAR3LPAR2ALDH1A1LMNA | |
| SCHEMBL9623948 | 0.98 | TSHR (0.42) | TSHRLPAR3LPAR2ALDH1A1LMNA | |
| SCHEMBL12403539 | 0.91 | TSHR (0.42) | TSHRLPAR3LPAR2ALDH1A1LMNA | |
| SCHEMBL25559091 | 0.89 | TSHR (0.38) | TSHRLPAR3LPAR2ALDH1A1LMNA | |
| SCHEMBL4300325 | 0.80 | — | — | |
| SCHEMBL12361992 | 0.80 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL13538316 | 0.80 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL19193963 | 0.80 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL27240088 | 0.80 | MAPK1 (0.35) | ALDH1A1 | |
| SCHEMBL27240036 | 0.80 | MAPK1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958042-B2 | Reactions of olefin derivatives in the presence of metathesis catalysts | UMICORE AG & CO. KG (DE) | 2024-04-16 | — | — | US | disclosed |
| EP-3116848-B1 | PROCESS INVOLVING CROSS METATHESIS OF OLEFINS | GIVAUDAN SA (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-20220055025-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-11161104-B2 | Reactions of olefin derivatives in the presence of methathesis catalysts | UMICORE AG & CO. KG | 2021-11-02 | — | — | US | disclosed |
| US-20210046466-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2021-02-18 | — | — | US | disclosed |
| CN-111788189-A | Reaction of olefin derivatives in the presence of metathesis catalysts | 优美科股份公司及两合公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-106103403-B | Process comprising cross metathesis of olefins | 奇华顿股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20190100504-A1 | Process Involving Cross Metathesis of Olefins | GIVAUDAN S.A. (CH) | 2019-04-04 | — | — | US | disclosed |
| US-10144720-B2 | Process involving cross metathesis of olefins | GIVAUDAN S.A. (CH) | 2018-12-04 | — | — | US | disclosed |
| EP-3116848-A1 | PROCESS INVOLVING CROSS METATHESIS OF OLEFINS | Givaudan S.A. (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368888-A1 | Process Involving Cross Metathesis of Olefins | GIVAUDAN S.A. (CH) | 2016-12-22 | — | — | US | disclosed |
| WO-2015136093-A1 | PROCESS INVOLVING CROSS METATHESIS OF OLEFINS | GIVAUDAN SA (CH) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046466-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | MDK, MTR, MUSK | TSHR 1339/4885LPAR3 4220/4885LPAR2 4130/4885 |
| US-11161104-B2 | Reactions of olefin derivatives in the presence of methathesis catalysts | MDK, MTR, MUSK | TSHR 1339/4885LPAR3 4220/4885LPAR2 4130/4885 |
| US-20220055025-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | MDK, MTR, MUSK | TSHR 1339/4885LPAR3 4220/4885LPAR2 4130/4885 |
| US-10144720-B2 | Process involving cross metathesis of olefins | SYMPK, CLK1, MOK | TSHR 3793/4885LPAR3 4482/4885LPAR2 3627/4885 |
| US-11958042-B2 | Reactions of olefin derivatives in the presence of metathesis catalysts | SYMPK, MDK, HCK | TSHR 4295/4885LPAR3 3890/4885LPAR2 3923/4885 |
| US-20190100504-A1 | Process Involving Cross Metathesis of Olefins | SYMPK, CLK1, MOK | TSHR 3793/4885LPAR3 4482/4885LPAR2 3627/4885 |
| US-20160368888-A1 | Process Involving Cross Metathesis of Olefins | SYMPK, CLK1, MOK | TSHR 3793/4885LPAR3 4482/4885LPAR2 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.